Amanda Hays is Scientific Officer at BioAgilytix, a contract research organization (CRO) that supports comprehensive biomedical services for all stages and modalities of drug development. Here, Hays shares how bioanalysis has evolved tremendously with the emergence of advanced gene editing technologies and explains the important role of American Association of Pharmaceutical Scientists (AAPS) in enabling the collaboration between scientists and companies across diverse scientific disciplines - highlighting the recent National Biotech Conference (NBC).

Download your free copy of the whitepaper "Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development" here.